The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
RUZURGI (ORSPEC Pharma Pty Ltd)
Product name
RUZURGI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
127 (255 working days)
Active ingredients
amifampridine
Registration type
NCE/NBE
Indication
RUZURGI (tablet) is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above.